BioTuesdays
Feature

In conversation with Dr. Shai Yarkoni

By Len Zehr As a co-founder and CEO of Cellect Biotechnology (TASE:CLBD), Dr. Shai Yarkoni has more than 15 years of clinical and management experience in the biopharmaceutical industry. He is the founder of five start...

April 21, 2015
Feature

In conversation with Greg Trudel

By Len Zehr As president and CEO of Encision (OTCQB:ECIA), Greg Trudel, who moved into the executive suite in December 2013, has always had a strong interest in energy, dating back to various leadership posts with...

April 14, 2015
Feature

Relmada championing four pain drug candidates

By Len Zehr Startup Relmada Therapeutics (OTCQB:RLMD) is in the enviable position of having multiple shots on goal in the world’s largest drug prescription market: the treatment of pain. “It is very unusual for a...

April 7, 2015
Feature

In conversation with Dr. Isaac Ciechanover

By Len Zehr As president and CEO of Atara Biotherapeutics (NASDAQ:ATRA), Dr. Isaac Ciechanover has spent the past 20 years working with entrepreneurs and life sciences organizations to advance medicine through...

March 31, 2015
Feature

Actinium gearing up for pivotal trial in second half

By Len Zehr Actinium Pharmaceuticals (NYSE MKT:ATNM) expects to begin a Phase 3 trial in the second half this year of its Iomab-B drug candidate as a conditioning agent in elderly patients with relapsed/refractory acute...

March 24, 2015
Feature

Ocular Therapeutix eyeing sustained drug delivery

By Len Zehr Ocular Therapeutix (NASDAQ:OCUL) is aiming to transform the treatment of eye diseases with sustained-release therapeutics, creating a paradigm shift from frequently administered topical ophthalmic drugs to...

March 17, 2015
Feature

Synergy Disc Replacement sets global sales plan

By Len Zehr After an initial market launch of its revolutionary SYNERGY DISC that exceeded expectations in Germany last year, closely-held Synergy Disc Replacement Inc. (SDRI) is planning to expand distribution...

March 3, 2015
Feature

In conversation with Steve Damon

By Len Zehr As president, CEO and a co-founder of closely-held 4P Therapeutics, a leading developer of transdermal patches, Steve Damon cut his teeth in the sector at Altea Therapeutics and Durect. He was responsible...

February 24, 2015
Feature

Neovasc launching Reducer in Europe for RA

Neovasc (NASDAQ:NVCN; TSX:NVC) has begun an initial launch in Europe to introduce its implantable Reducer medical device for the treatment of refractory angina (RA) in advanced-stage cardiovascular patients. Alexei...

February 17, 2015
Feature

In conversation with David Giljohann

By Len Zehr As CEO of closely-held AuraSense Therapeutics, Dr. David Giljohann is one of the original inventors of the company’s technology for first-in-class therapies based on its proprietary spherical nucleic acid...

February 10, 2015
Feature

Dipexium advancing EU approval strategy for Locilex

By Len Zehr With its Phase 3 program underway in the U.S., Dipexium (NASDAQ:DPRX) has begun the regulatory process with the European Medicines Agency (EMA) for its Locilex topical treatment for diabetic foot infections...

February 3, 2015
Feature

In conversation with Allen Krantz

By Len Zehr As the founder, president and CEO of Advanced Proteome Therapeutics (TSX-V:APC; Frankfurt:OE8), Dr. Allen Krantz has successfully transitioned a career in academia to the biotech sector. From 1968 to 1974...

January 27, 2015
Feature

EndyMed expands sales effort in U.S.

By Len Zehr After five years of selling its skin rejuvenation devices to medical professionals through a distributor, EndyMed Medical (TASE:ENDY) has launched a U.S.-based direct sales operation through subsidiary...

January 20, 2015
Feature

Season’s Greetings (and JPM 2015)

Wow! What a great year 2014 turned out to be! On behalf of everyone at BioTuesdays, I would like to wish you all a safe and happy holiday season. After taking a short break to spend time with family and friends, we will...

December 19, 2014
Feature

Nuvo Research to release Phase 2 WF10 data in Q1

By Len Zehr Nuvo Research (TSX:NRI) plans to release, in the first quarter of 2015, the results of a confirmatory Phase 2 study for a potential blockbuster allergic rhinitis drug, WF10, which could be a game-changing...

December 2, 2014
Feature

rEVO Biologics spearheading preeclampsia treatment

By Len Zehr Closely held rEVO Biologics is enrolling patients in a Phase 3 clinical trial of its ATryn recombinant human antithrombin for the treatment of early-onset preeclampsia, with top-line data expected in the...

November 11, 2014
Feature

CytoTools awaiting India clearance for DermaPro

By Len Zehr CytoTools AG (DE000A0KFRJ1/T5O) of Germany and its Indian marketing partner, Centaur Pharmaceuticals, expect to receive regulatory clearance in the current quarter in India for lead product, DermaPro, to...

November 4, 2014